$88b Loss Hits Major Australian Pharmaceutical Company

Australia's pharmaceutical giant faces an $88 billion loss, marking a significant downturn in its investment history. This financial crisis highlights challenges beyond former President Trump's influence, affecting the company's reputation and future prospects. Analysts are concerned about the long-term implications for the industry.

Read the full story at Sydney Morning Herald→